FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes ...

The US Food and Drug Administration approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor ...

The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients ...

The history of weight loss medicines reads like a Greek tragedy. However, the biology behind the new GLP-1 agonists suggests ...

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...

Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs, but that number falls ...

Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

The U.S. Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the ...

Many people with type 2 diabetes can manage their blood sugar levels with lifestyle changes, including exercise and nutrition ...

Their symptom improvement was likely thanks to their weight loss, the FDA said. Zepbound is a glucagon-like peptide 1 drug ...